Literature DB >> 16020630

Calcium channel blocker inhibits Western-type diet-evoked atherosclerosis development in ApoE-deficient mice.

Jan Kyselovic1, Peter Martinka, Zuzana Batova, Andrea Gazova, Theophile Godfraind.   

Abstract

Calcium channel blockers slow the progression of atherosclerosis. The purpose of the present experiments was to examine the action of lacidipine in a condition that accelerates the development of atherosclerosis in order to test the hypothesis that the protective action of lacidipine in atherosclerosis is unrelated to the reduction of blood pressure. Male ApoE-deficient mice (6 weeks old) were exposed either to normal chow (ND) or to a Western-type diet (WD, adjusted calorie diet containing 42% from fat) for 8 weeks. Western-type diet induced a reduction of nitric oxide (NO)-mediated endothelium-dependent relaxation to acetylcholine (Max relaxation % = 55.8 +/- 2 for ND and 46.6 +/- 2 for WD, n = 8, p < 0.05). Dose-relaxation curves to S-nitroso-N-acetylpenicillamine (SNAP) NO donor were also significantly rightward-shifted (n = 7, ANOVA, p < 0.01) in WD compared with ND arteries. Chronic treatment of WD mice with lacidipine (1 and 3 mg/kg/day) increased significantly the acetylcholine-evoked relaxation (to 76.6 +/- 3.5%, n = 6, ANOVA, p < 0.001) and prevented the loss of responsiveness to SNAP in mice exposed to WD. Plasma renin activity and endothelin-1 plasma levels as well as thiobarbituric acid-reactive substance levels in kidneys were significantly lower in WD mice treated with lacidipine than in untreated ones. In mice exposed to WD lacidipine reduced extension of atherosclerotic lesions, renal injury and increase in blood pressure. Experimental data indicate that inhibition of Western-type diet-evoked alterations is related to both antioxidant and vasoactive properties of lacidipine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020630     DOI: 10.1124/jpet.105.089847

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis.

Authors:  Théophile Godfraind
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

2.  Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.

Authors:  Günay Yetik Anacak; Levent Ustünes; Ozlem Yilmaz Dilsiz; Adviye Ergul
Journal:  Vascul Pharmacol       Date:  2010-08-12       Impact factor: 5.773

3.  Vasodilator efficacy of nitric oxide depends on mechanisms of intracellular calcium mobilization in mouse aortic smooth muscle cells.

Authors:  C E Van Hove; C Van der Donckt; A G Herman; H Bult; P Fransen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

Review 4.  Self-eating in the plaque: what macrophage autophagy reveals about atherosclerosis.

Authors:  Ismail Sergin; Babak Razani
Journal:  Trends Endocrinol Metab       Date:  2014-04-17       Impact factor: 12.015

5.  Heavy metal poisoning and cardiovascular disease.

Authors:  Eman M Alissa; Gordon A Ferns
Journal:  J Toxicol       Date:  2011-09-08

Review 6.  Discovery and Development of Calcium Channel Blockers.

Authors:  Théophile Godfraind
Journal:  Front Pharmacol       Date:  2017-05-29       Impact factor: 5.810

7.  eNOS-dependent antisenscence effect of a calcium channel blocker in human endothelial cells.

Authors:  Toshio Hayashi; Tomoe Yamaguchi; Yasufumi Sakakibara; Kumiko Taguchi; Morihiko Maeda; Masafumi Kuzuya; Yuichi Hattori
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

8.  Azelnidipine Inhibits the Differentiation and Activation of THP-1 Macrophages through the L-Type Calcium Channel.

Authors:  Hiroshi Komoda; Aya Shiraki; Jun-Ichi Oyama; Toshiyuki Nishikido; Koichi Node
Journal:  J Atheroscler Thromb       Date:  2018-02-03       Impact factor: 4.928

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.